ch14.18/CHO

DRUG5 trials

Conditions

NeuroblastomaNeuroblastoma Recurrent

Phase 1

Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)

NCT01701479

St. Anna KinderkrebsforschungNeuroblastoma

Start: 2012-01-31End: 2020-12-31Target: 288Updated: 2020-07-14

ch14.18/CHO Bridging Study

CompletedNCT01704872

St. Anna KinderkrebsforschungNeuroblastoma

Start: 2005-07-31End: 2012-03-31Updated: 2020-10-22

Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma

Active, not recruitingNCT02914405

University Hospital Southampton NHS Foundation TrustNeuroblastoma

Start: 2018-05-24End: 2026-09-30Target: 44Updated: 2026-04-28

Phase 2

CH14.18 1021 Antibody and IL2 After Haplo SCT in Children With Relapsed Neuroblastoma

CompletedNCT02258815

University Children's Hospital TuebingenNeuroblastoma Recurrent

Start: 2010-08-31End: 2022-12-31Target: 35Updated: 2023-12-08

Phase 3

High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)

RecruitingNCT01704716

St. Anna KinderkrebsforschungNeuroblastoma

Start: 2002-02-28End: 2026-09-30Target: 3300Updated: 2020-10-23

Journal of Clinical Oncology2023-06-011 citations

Novel Chemoimmunotherapy Improves Outcomes in Neuroblastoma

Oncology Times2022-06-04

A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma–LuDO-N

Frontiers in Pediatrics2022-03-1026 citations

Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment

Frontiers in Immunology2021-07-2219 citations

Risk factors in the HR-NBL-1/SIOPEN study in patients receiving dinutuximab beta (DB) based immunotherapy.

Journal of Clinical Oncology2020-05-20

Eighty per cent more patients in 10 years of UK molecular radiotherapy

Nuclear Medicine Communications2019-05-0610 citations

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.

2018-11-12294 citations

The influence of surgical excision on survival in high-risk neuroblastoma revisited after introduction of ch14.18/CHO immunotherapy in the HR-NBL1/SIOPEN trial.

Journal of Clinical Oncology2018-05-2010 citations

The randomised induction for high-risk neuroblastoma comparing COJEC and N5-MSKCC regimens: Early results from the HR-NBL1.5/SIOPEN trial.

Journal of Clinical Oncology2018-05-209 citations

Immunotherapy with anti-GD2 antibody ch14.18/CHO±IL2 within the HR-NBL1/SIOPEN trial to improve outcome of high-risk neuroblastoma patients compared to historical controls.

Journal of Clinical Oncology2018-05-207 citations

Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.

2017-03-02251 citations

Toxicity and outcome of anti-GD<sub>2</sub> antibody ch14.18/CHO in front-line, high-risk patients with neuroblastoma: Final results of the phase III immunotherapy randomisation (HR-NBL1/SIOPEN trial).

Journal of Clinical Oncology2016-05-2019 citations

Phase II clinical trial with long-term infusion of anti-GD<sub>2</sub> antibody ch14.18/CHO in combination with interleukin-2 (IL2) in patients with high risk neuroblastoma.

Journal of Clinical Oncology2016-05-204 citations

Prognostic factors in stage 4 neuroblastoma treated with busulphan-melphalan: Report from the European HR-NBL1/Siopen trial.

Journal of Clinical Oncology2016-05-201 citations

Abstract A032: Immunotherapy with ch14.18/CHO in combination with IL2 is active and effective in high-risk relapsed/refractory neuroblastoma patients

Cancer Immunology Research2016-01-011 citations

Long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 (IL2) activity and efficacy in high-risk relapsed/refractory neuroblastoma patients.

Journal of Clinical Oncology2015-05-2012 citations

Haploidentical stem cell transplantation and subsequent immunotherapy with antiGD2 antibody for patients with relapsed metastatic neuroblastoma.

Journal of Clinical Oncology2015-05-2010 citations

Immunotherapy (IT) with ch14.18/CHO for high-risk neuroblastoma: First results from the randomised HR-NBL1/SIOPEN trial.

Journal of Clinical Oncology2014-05-206 citations

Validation of the MIBG SIOPEN scoring method in two independent high-risk neuroblastoma trials.

Journal of Clinical Oncology2014-05-201 citations

ch14.18/CHO

Sponsors

Conditions

Phase 1

Phase 2

Phase 3

Related Papers